Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,250 | 1 | 41.2% |
| Unspecified | $975.00 | 2 | 32.1% |
| Travel and Lodging | $651.84 | 3 | 21.5% |
| Food and Beverage | $157.13 | 3 | 5.2% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bausch & Lomb Americas Inc. | $1,250 | 1 | $0 (2024) |
| Spark Therapeutics, Inc. | $975.00 | 2 | $0 (2020) |
| Allergan Inc. | $743.09 | 4 | $0 (2018) |
| TOPCON CORPORATION | $39.50 | 1 | $0 (2020) |
| TissueTech, Inc. | $26.38 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,250 | 1 | Bausch & Lomb Americas Inc. ($1,250) |
| 2020 | $689.50 | 2 | Spark Therapeutics, Inc. ($650.00) |
| 2019 | $325.00 | 1 | Spark Therapeutics, Inc. ($325.00) |
| 2018 | $743.09 | 4 | Allergan Inc. ($743.09) |
| 2017 | $26.38 | 1 | TissueTech, Inc. ($26.38) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA, LOTEMAX | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,250.00 | General |
| Category: Ophthalmology | ||||||
| 02/26/2020 | Spark Therapeutics, Inc. | — | — | Cash or cash equivalent | $650.00 | Research |
| Study: A PHASE 1/2 SAFETY STUDY IN SUBJECTS WITH CHM (CHOROIDEREMIA) GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VECTOR TO DELIVER THE NORMAL HUMAN CHM GENE [AAV2-HCHM] TO THE RETINA | ||||||
| 01/31/2020 | TOPCON CORPORATION | OCT-TRITON (Device) | Food and Beverage | Cash or cash equivalent | $39.50 | General |
| Category: OPHTHALMIC INSTRUMENT | ||||||
| 01/17/2019 | Spark Therapeutics, Inc. | — | — | Cash or cash equivalent | $325.00 | Research |
| 05/19/2018 | Allergan Inc. | — | Travel and Lodging | In-kind items and services | $359.60 | General |
| 05/19/2018 | Allergan Inc. | — | Travel and Lodging | In-kind items and services | $256.24 | General |
| 05/19/2018 | Allergan Inc. | — | Food and Beverage | In-kind items and services | $91.25 | General |
| 05/19/2018 | Allergan Inc. | — | Travel and Lodging | In-kind items and services | $36.00 | General |
| 04/10/2017 | TissueTech, Inc. | Prokera (Device), AmnioGraft, AmnioGuard | Food and Beverage | Cash or cash equivalent | $26.38 | General |
| Category: Medical Device (510K) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1/2 SAFETY STUDY IN SUBJECTS WITH CHM (CHOROIDEREMIA) GENE MUTATIONS USING AN ADENO-ASSOCIATED VIRUS SEROTYPE 2 VECTOR TO DELIVER THE NORMAL HUMAN CHM GENE [AAV2-HCHM] TO THE RETINA | Spark Therapeutics, Inc. | $650.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 438 | 803 | $377,023 | $35,656 |
| 2022 | 8 | 442 | 830 | $386,129 | $32,931 |
| 2021 | 7 | 407 | 895 | $471,354 | $39,784 |
| 2020 | 5 | 317 | 613 | $339,897 | $29,371 |
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 92014 | Established patient complete exam of visual system | Office | 2023 | 115 | 180 | $126,000 | $11,121 | 8.8% |
| 67028 | Injection of drug into eye | Office | 2023 | 34 | 121 | $133,463 | $9,066 | 6.8% |
| 92134 | Imaging of retina | Office | 2023 | 179 | 386 | $62,532 | $8,005 | 12.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 49 | 54 | $31,158 | $4,666 | 15.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 12 | $9,276 | $1,425 | 15.4% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 12 | 12 | $9,996 | $783.81 | 7.8% |
| 92082 | Exam of visual field with intermediate testing | Office | 2023 | 38 | 38 | $4,598 | $589.77 | 12.8% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 147 | 248 | $173,600 | $14,349 | 8.3% |
| 67028 | Injection of drug into eye | Office | 2022 | 31 | 112 | $123,536 | $8,215 | 6.7% |
| 92134 | Imaging of retina | Office | 2022 | 170 | 374 | $60,588 | $7,392 | 12.2% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 21 | 21 | $17,493 | $1,562 | 8.9% |
| 92082 | Exam of visual field with intermediate testing | Office | 2022 | 39 | 39 | $4,719 | $563.52 | 11.9% |
| 92273 | Measurement of retinal and optic nerve function | Office | 2022 | 11 | 12 | $2,448 | $369.26 | 15.1% |
| 92083 | Exam of visual field with extended testing | Office | 2022 | 12 | 13 | $1,963 | $319.86 | 16.3% |
| 92133 | Imaging of optic nerve | Office | 2022 | 11 | 11 | $1,782 | $159.80 | 9.0% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2021 | 136 | 270 | $189,000 | $17,958 | 9.5% |
| 67028 | Injection of drug into eye | Office | 2021 | 30 | 130 | $151,320 | $10,245 | 6.8% |
| 92134 | Diagnostic imaging of retina | Office | 2021 | 145 | 397 | $105,205 | $8,646 | 8.2% |
| 92004 | Eye and medical examination for diagnosis and treatment, new patient, 1 or more visits | Office | 2021 | 19 | 19 | $15,827 | $1,509 | 9.5% |
| 92082 | Measurement of field of vision during daylight conditions, intermediate examination | Office | 2021 | 47 | 49 | $5,586 | $729.26 | 13.1% |
| 92083 | Measurement of field of vision during daylight conditions, extended examination | Office | 2021 | 18 | 18 | $2,628 | $453.24 | 17.2% |
| 92133 | Diagnostic imaging of optic nerve of eye | Office | 2021 | 12 | 12 | $1,788 | $243.72 | 13.6% |
| 67028 | Injection of drug into eye | Facility | 2020 | 26 | 111 | $129,204 | $9,433 | 7.3% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Facility | 2020 | 82 | 126 | $88,200 | $8,447 | 9.6% |
| 92134 | Diagnostic imaging of retina | Facility | 2020 | 102 | 251 | $52,307 | $5,438 | 10.4% |
About Dr. Jacque Duncan, MD
Dr. Jacque Duncan, MD is a Ophthalmology healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942252978.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jacque Duncan, MD has received a total of $3,034 in payments from pharmaceutical and medical device companies, with $1,250 received in 2024. These payments were reported across 9 transactions from 5 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1,250).
As a Medicare-enrolled provider, Duncan has provided services to 1,604 Medicare beneficiaries, totaling 3,141 services with total Medicare billing of $137,741. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Practice Information
- Specialty Ophthalmology
- Location San Francisco, CA
- Active Since 05/17/2006
- Last Updated 07/09/2007
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1942252978
Products in Payments
- MIEBO (Drug) $1,250
- OCT-TRITON (Device) $39.50
- Prokera (Device) $26.38
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in San Francisco
Dr. Daniel Schwartz, M.d, M.D
Ophthalmology — Payments: $8.0M
Shan Lin, Md, MD
Ophthalmology — Payments: $437,860
Dr. Eugene De Juan, Md, MD
Ophthalmology — Payments: $349,911
Dr. H Tanaka, Md, MD
Ophthalmology — Payments: $326,711
Dr. Jay Stewart, Md, MD
Ophthalmology — Payments: $295,001
Dr. Scott So, M.d, M.D
Ophthalmology — Payments: $172,800